Literature DB >> 3108874

Valpromide but not sodium hydrogen divalproate inhibits epoxide hydrolase in human liver.

G M Pacifici, A Rane.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3108874     DOI： 10.1111/j.1600-0773.1987.tb01743.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN： 0901-9928


× No keyword cloud information.
  4 in total

Review 1.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 2.  Clinical pharmacology of valpromide.

Authors:  M Bialer
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

3.  Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity.

Authors:  A Haj-Yehia; M Bialer
Journal:  Pharm Res       Date:  1989-08       Impact factor: 4.200

4.  Valpromide is a poor inhibitor of the cytosolic epoxide hydrolase.

Authors:  G M Pacifici; A Temellini; L Giuliani; A Rane; H Thomas; F Oesch
Journal:  Arch Toxicol       Date:  1989       Impact factor: 5.153
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.